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Background: Ischemia/reperfusion (I/R) injury is a major contributory factor to cardiac dysfunction and
infarct size that determines patient prognosis after acute myocardial infarction. During the last 20 years,
since the appearance of the ﬁrst publication on ischemic preconditioning (IP), our knowledge of this
phenomenon has increased exponentially.
Results and conclusion: Basic scientiﬁc experiments and preliminary clinical trials in humans suggest
that IP confers resistance to subsequent sustained ischemic insults not only in the regional tissue but also
in distant organs (remote ischemic preconditioning), which may provide a simple, cost-effective means
of reducing the risk of perioperative myocardial ischemia. The mechanism may be humoral, neural, or
a combination of both, and involves adenosine, bradykinin, protein kinases and KATP channels, although
the precise end-effector remains unclear. This review describes different signaling pathways involved in
acute ischemic preconditioning in detail.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Ischemic preconditioning (IP) is a powerful innate mechanism
to protect against ischemic reperfusion (IR) injury. IP is an early
stress response that occurs during repeated episodes of brief and
moderate vascular occlusion and reperfusion and can render the
ischemic organ more tolerant to a subsequent ischemic insult.1–3
Since its ﬁrst description by Murry et al.4 (1986) in the heart, IP has
been shown to reduce the extent of myocardial infarct size as well
as the damage to skeletal muscle, brain or hepatic tissue induced by
subsequent exposure to severe ischemia in a variety of species.5–7
Different phases of IP have been observed: the early phase, referred
to as ‘‘classic’’ preconditioning, is observed after brief periods of
ischemia and is sustained for approximately 3 h. A delayed phase of
preconditioning has been demonstrated at 18–24 h following brief
ischemic insult.8 A more intriguing form of ischemic pre-
conditioning is preconditioning at a distance or remote ischemic
preconditioning (RIP) which provides protection of organs distant
to the ischemic insult by exposure of a remote organ to brief
periods of ischemia.9 RIP has been extensively used in clinical
practice. Though the precisemechanisms and pathways involved in
these different types of IP still require further investigation and
research we present a general overview of their known effectors,
mediators and triggers.ciates Ltd. Published by Elsevier Lt2. Mechanisms involved in preconditioning
Although intense research has been undertaken in an effort to
determine the exact mechanism involved in ischemic pre-
conditioning over the last 2 decades, the pathways involved in
signal transduction have only partially emerged (summarized in
Fig. 1). Various agonists that confer cardioprotection have been
recognized but exactly how they elicit protection against ischemic
insult remains unclear.
The initial ‘‘early’’ preconditioning does not appear to depend on
new protein synthesis because of the rapid onset and because
blockade of protein synthesis does not block early IP. The second
window is, however, mediated by newgene expression, rather than
posttranslational modiﬁcation of proteins. The mechanisms of the
second window are different and will not be covered in this review.
The reader is referred to other excellent reviews on this area.103. Role of adenosine
Adenosine mediates its different cardiovascular actions via four
known receptor subtypes (A1, A2A, A2B and A3). All are expressed in
different cell types of the heart and blood vessels, but A1A receptors
(A1ARs) and A2ARs are expressed only in adult ventricular myo-
cytes.11,12 However, there is no deﬁnite evidence of the location of
A3 or A2BARs on adult mammalian myocytes.
Of all these receptors, A1ARs are the most widely studied and
well characterized adenosine receptors. A1AR agonism has been
linked to different kinase systems including PKC, MAPKs, P13d. All rights reserved.
Fig. 1. Signalling pathways in ischemic preconditioning.
U. Sadat / International Journal of Surgery 7 (2009) 490–498 491kinase and Akt.13–15 A1AR antagonism has been found to block PKC
translocation in ischemic myocardium.16 In non-ischemic myocar-
dium A1AR mediated stimulation of PKC-3
17 and PKC-g18 has been
observed. Both PKC and KATP channels additively contribute to the
acute AR mediated cardioprotection.19,20 MAPK involvement in
A1AR mediated cardioprotection has also been observed, particu-
larly in the P38 MAPK pathway.21 According to Liu and Hofmann,
A1AR dependent p38 MAPK signaling can stimulate cardiac protein
phosphatase 2a activity.22 ARs also activate P13 kinase via tyrosine
kinase activation. This activates Akt/PKB which in turn results in
phosphorylation of BAD and phosphorylation and inactivation of
GSK3b,23 both of which improve cell survival. ERK1/2 activation has
also been implicated in cardioprotection.24 These multiple
signaling pathways converge on mitochondrial KATP channels, the
precise function of which remains controversial.
The A2Rs are classiﬁed as A2AARs and A2BARs. A number of
studies support A2AR mediated cardioprotection during ischemia–
reperfusion. Vinten-Johansen and colleagues have reported A2AR-
dependent protection by limiting the injurious effects of neutrophil
activation and proapoptotic signaling.25 Yang and colleagues have
identiﬁed CD4þ T lymphocytes as the sole mediators/regulators of
A2AR agonism. Their latter work has shown that agonism of A2AARs
on CD4þ T lymphocytes reduces the accumulation of these cells
and neutrophils in ischemic tissues.26 This leads to a reduction in
the infarct size. Headrick and colleagues suggest that the apparent
functional beneﬁts result from the positive inotropic effects of A2AR
mediated elevations in adenosine 30, 50-cyclic monophosphate
rather than direct protective action of A2AR agonism.
15 However,
controversy remains about the interpretation of the possible
impact of functional changes in different in vitro and isolated
animal models used for A2AR studies.
27–31
The A2BA receptor is the least well studied adenosine receptor
and the evidence about its expression in cardiovascular tissue
remains indirect. The precise signaling pathways involved in A2BAR
responses also remain unclear. But it is known that this receptor has
low afﬁnity for adenosine and requires high levels of adenosine for
activation. As levels of adenosine are highest during the ischemia,
and fall rapidly following the ischemic insult, it is suggested that
the majority of A2BAR mediated responses result from their acti-
vation during the initial insult. This results in the anti-ﬁbrotic and
anti-proliferative action of A2BAR on cardiac ﬁbroblasts, thereby
regulating post-ischemic remodeling.32A3ARs have been recently identiﬁed and cloned.
33 This subtype
has been uniformly shown to mediate cardioprotective effects.
Although their expression in cardiomyocytes has not been directly
identiﬁed, A3ARs have been identiﬁed in human eosinophils.
34
Although one way of affording cardioprotection is the inhibition of
resident mast cell degranulation, however, it is unclear whether
A2BARs have a role in this process. Nonetheless, this receptor
subtype appears to share a few similarities with A1AR, e.g.
involvement of PKC, P13 kinase, ERK and mitochondrial KATP
channels. Similar to A1AR, A3ARs appear to trigger ERK1/2 and Akt
activation.24 Though avian studies have demonstrated triggering of
the phospholipase D/Rho-A pathway by A3ARs, their role in
mammalian myocytes is questionable.35
4. Role of bradykinin and ROS
Besides adenosine, bradykinin (BK) is one of the important
autacoids released by ischemic myocardium and appears to be the
principle endogenous trigger of preconditioning. It binds to GiPCRs,
leading to the activation of P13-k, phosphorylation of Akt and
ERK1/2 (without the involvement of EGFR), generation of nitric
oxide (NO), activation of PKG and opening of mitochondrial KATP.
This results in the generation of reactive oxygen species (ROS). The
redox signaling by ROS leads to PKC activation which is thought to
result in preconditioning. This is in contrast to adenosine which
activates PKC directly, bypassing the redox signaling pathway.36
Mitochondrial electron transport appears to be responsible for ROS
generation.37 The evidence stems from the blockade of site III of the
mitochondrial respiratory chain by Myxo-a site III blocker, which
interferes with ROS generation.37 NO generation occurs by activa-
tion of BK receptors on the endothelial cells with subsequent
calcium mediated NO production via nitric oxide synthase (NOS).
NO activates guanylyl cyclase to produce cGMP which in turn
stimulates PKG.37–39
BK has been extensively shown clinically to afford car-
dioprotection, especially in patients undergoing coronary angio-
plasties. Massoud et al. have successfully shown that bradykinin
can be effectively used in the clinical setting without any side
effects and is as useful as IP and hence can be used prophylactically
to attenuate ischemia in selected patients undergoing revasculari-
zation.40 Although IP in these patients may partly result from
vasodilatation post-bradykinin administration, Massoud and co-
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arterial calibers had returned to normal size before inﬂation of
angioplasty balloon. Hence cardioprotection by BK was due to
mechanisms described above, independent of its vasodilatory role.
Feng has reported improvement in left ventricular and micro-
vascular function, both resulting from KCa and KATP channel
involvement.41 The activation of BKB2 receptors induces an intra-
cytoplasmic calcium inﬂux, which opens endothelial KCa channels.
The resulting hyperpolarization produces vessel relaxation. During
ischemic episodes, this hyperpolarization prevents intracellular
calcium overload, thereby affording cardiac and microvascular
protection. The involvement of KATP channels has been suggested
by Feng’s work; with glibenclamide inhibited BK-induced pre-
conditioning. Other workers have also reported similar results37,42–
44 with Driamov describing the antiarrhythmic effects of BK in the
form of reduction in the number of ventricular premature beats
(VPBs), ventricular tachycardia (VT) and ventricular ﬁbrillation
(VF). However, they speculate that BK is a mediator rather than the
trigger for preconditioning as hearts pharmacologically precondi-
tioned using BK showed a similar number of VPBs and episodes of
VT and VF.45 Feng and co-workers have reported that improvement
in ventricular function results from an increase in BAD phosphor-
ylation and inhibition of caspase 3 activation, thereby limiting
myocardial apoptosis.46 This is useful in limiting apoptosis
following cardioplegia arrest.
5. Role of acetylcholine
Acetylcholine (ACh) is an important mediator involved in
ischemic preconditioning. ACh receptors once stimulated lead to
the activation of P13-k g via Gi-coupling, leading to phosphoryla-
tion of Akt.47 However, there is cross-communication between
GiPCRs and EGFR, before the latter activates P13 kinase. Kreig et al.
have demonstrated that stimulation of GiPCR leads to a metal-
loproteinase-dependent cleavage of heparin-binding epidermal
growth factor-like growth factor (HB-EGF) from membrane-asso-
ciated proHB-EGF.48 The exact metalloproteinase responsible for
HB-EGF cleavage is not known. The liberated HB-EGF then activates
the EGFR by binding to its ectodomain49 with the EGFR then
forming a complex that includes both Src kinase and P13 kinase.50
P13 kinase phosphorylates membrane phosphatidylinositol in the
three positions, which leads to the activation of PDK1 and PDK2 and
subsequent phosphorylation of the activation sites of Akt.47,51 This
leads to generation of nitric oxide (NO), activation of PKG and
opening of mitochondrial KATP channels.
52 The resulting generation
of reactive oxygen species (ROS) leads to PKC stimulation, similar to
that induced by BK, resulting in cardioprotection.47,53 These results
indicate that ACh (whether endogenous or exogenous) can play an
important role in affording cardioprotection. However, the clinical
implications for humans have not been exploited.
6. Nitric oxide (NO) signaling
Nitric oxide plays an important role in preconditioning-induced
cardioprotection. There is increasing evidence that NO plays
a prominent role both in triggering and mediating classicTable 1
Regional ischemia preconditioning studies.
Study Model Site of preconditioning stimulus Site
Przyklenk et al.9 Dog Circumﬂex occlusion LAD
Nakano et al.102 Rabbit (isolated heart) Cardiac ischemia Tota
Tanaka et al.103 Rabbit Cardiac ischemia Rem
Gho et al.104 Rat Cardiac ischemia Cardpreconditioning. The brief episode of ischemia/reperfusion causes
increased production of NO via nitric oxide synthase (NOS). This in
turn activates protein kinase C 3, tyrosine kinase and nuclear factor
kB (NF-kB) via cyclic guanosine monophosphate (cGMP)-depen-
dent signaling pathways.53,54 Qin et al. have shown that exogenous
NO triggers the preconditioning effect by initiating a cascade of
events leading to the opening of mitochondrial KATP channels,
which ultimately leads to the formation of ROS.55 However, NO has
also been shown to attenuate ischemic reperfusion injury by
regulating myocardial cellular levels by cyclic guanosine mono-
phosphate (cGMP) dependent (described above) and independent
signaling, the latter by redox reversible modiﬁcation of cysteine
residues via S-nitrosylation.56 Recent studies suggest that S-nitro-
sylation not only directly leads to the structural and functional
changes of modiﬁed proteins, but also provides protection to cells
by S-nitrosylation of some critical protein thiols and prevents them
from further oxidative modiﬁcation by ROS. It leads to redox
regulation of major cardiac Ca2þ-handling proteins such as L-type
Ca2þ channels, the sarcoplasmic reticulum (SR) Ca2þ-ATPase (SER-
CA2a) and Ca2þ release channel/ryanodine receptor (RyR2).56–58
The result is attenuation of calcium currents in cardiomyocytes,
leading to reduction of Ca2þ overload in ischemic-reperfused
hypercontractile hearts.59 Similarly in IPC hearts, increased S-
nitrosylation of cardiac myosin heavy and light chain 1 and myo-
mesin has been reported.59 Sun et al. have also reported the
S-nitrosylation of glycogen phosphorylase,60 which explains the
IPC induced attenuation of glycogenolysis described by Weiss
and colleagues.61 Other cardioprotective effects resulting from
S-nitrosylation of the proteins have been summarized by Sun et al.
and involve myocardial remodeling, antioxidant defenses, and
transcription regulation.57
7. KATP channels
KATP channels are composed of two distinct proteins, an
inwardly rectifying potassium (Kir) pre-subunit and the sulfonyl-
urea receptor (SUR). Currently there is evidence to suggest that
there are two KATP channels in a cell: a sarcolemmal channel
(sarcKATP channel) and an inner mitochondrial membrane channel
(mitoKATP channel).
62
Noma hypothesized that opening of the sarcolemmal KATP
channel is induced by hypoxia, ischemia or pharmacological agents.
This shortens the cardiac action potential duration (APD) by
accelerating phase 3 repolarisation. This would inhibit Ca2þ entry
into the cell via L-type channels, preventing Ca2þ overload.63 This
was conﬁrmed by Cole and colleagues when they demonstrated
that KATP channel opener pinacidil could improve ventricular
function in guinea pigs while non-selective KATP channel antagonist
glibenclamide attenuated the APD shortening.64 Similar effects on
APD were reported by other investigators in other species.65–67 The
precise signaling pathways by which sarcKATP channels is activated
during IPC is unknown. Liu and colleague68 have demonstrated that
transient ischemia opens the KATP channels following the syner-
gistic action produced by PKC phosphorylation and adenosine
receptor activation. The functional coupling of PKC with sarcKATP
channels has also been described by Light et al.33 There is alsoof index ischemia Endpoint Proposed mechanism
occlusion Infarct size reduction Not identiﬁed
l LV: global ischemia Infarct size reduction Not applicable
ote myocardial preconditioning Infarct size reduction Heat shock proteins
iac ischemia Infarct size reduction Neurogenic pathway
Table 2
Remote ischemic preconditioning studies using hind limb as preconditioning stimulus.
Study Model Site of preconditioning
stimulus
Site of index ischemia Endpoint Proposed mechanism
Oxman et al.105 Rat Hind limb Cardiac ischemia Decrease in reperfusion arrhythmias Norepinephrine
Birnbaum et al.106 Rabbit Gastrocnemius muscle
and reduced ﬂow
Cardiac ischemia Reduced infarct size Not identiﬁed
Kharbanda et al.107 Pig Hind limb Cardiac ischemia Reduced infarct size Adrenergic pathway and blockade of reserpine
Gu¨naydin et al.108 Human Upper limb Cardiac ischemia LDH, CK release (inconclusive) Enhanced anaerobic glycolysis
Xia et al.109 Sheep Iliac artery Cardiac ischemia Pulmonary function and pulmonary
vascular resistance
KATP channels – pulmonary vascular dilatation
and myocardial protection
Weinbrenner et al.87 Rat Infrarenal Cardiac ischemia Reduced infarct size Opioid receptors and PKC; humoral pathway
Li et al.110 Mice Hind limb Cardiac ischemia Reduced infarct size; delayed NFK and iNOS
Konstantinov et al.111 Rat Hind limb Cardiac ischemia in
transplanted heart
Reduced infarct size KATP channels modulation in recipient
Konstantinov et al.112 Mouse Hind limb Cardiac ischemia Reduced infarct size Inﬂammatory gene suppression
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to lessen the inhibition of sarcolemmal Na–K-ATPase which nor-
mally occurs in the acute phase of ischemia. Digoxin, which is an
inhibitor of Na–K-ATPase, has been shown to reduce the infarct
limiting effect of IPC.69 By Na–K-ATPase inhibition, digoxin
increases the amount of the subsarcolemmal ATP and subsequently
prevents the sarcKATP channel opening during IPC. The protective
effect of KATP channel openers is not abolished by digoxin, because
of their direct effect on the channel, indicating a cardioprotective
effect independent of intracellular ATP concentration. The sarcKATP
channel opening leads to hyperpolarization that may lead to acti-
vation of themitoKATP channel, however, there is no direct evidence
about the underlyingmechanism for the inter-channel cross-talk.62
Evidence for the direct role of mitoKATP channels in car-
dioprotection comes from Garlid’s work,70 but to date it remains
unclear as towhether it is a trigger or distant effector. There are few
reports that support involvement of the mitoKATP channels as an
end-effector and trigger.71,72 The underlying mechanisms by which
mitoKATP channels are activated are quite similar to that of sarcKATP
channels, with activation and translocation of PKC central to the
opening of mitoKATP channel. Their opening leads to a reduction in
ischemia-induced elevation of mitochondrial Ca2þ levels, which are
usually attributed to ischemia–reperfusion injury.8. Role of protein kinases C
So far it has been understood that these cardioprotective
agonists couple to phospholipase C (PLC), activation of which
causes hydrolysis of phosphatidylinositol 4,5 bisphosphate (PIP 2)
generating inositol 1,3,4 triphosphate (IP3) and diacylglycerol
(DAG). The latter acts as a secondary messenger to stimulate
translocation of protein kinase C (PKC), which subsequently acts asTable 3
Remote ischemic preconditioning studies using mesenteric ischemia as preconditioning
Study Model Site of preconditioning
stimulus
Site of index
ischemia
Gho et al.104 Rat Mesenteric and renal Cardiac ischemia
Schoemaker et al.113 Rat Mesenteric ischemia Cardiac ischemia
Leim et al.114 Rat Mesenteric ischemia Cardiac ischemia
Wang et al.115 Rat Mesenteric ischemia Cardiac ischemia
Wolfrum et al.116 Rat Mesenteric ischemia Cardiac ischemia
Wolfrum et al.117 Rat Mesenteric ischemia Cardiac ischemia
Patel et al.118 Rat Mesenteric ischemia Cardiac ischemia
Tang et al.119 Rat Mesenteric ischemia Cardiac ischemia
Xiao et al.120 Rat Mesenteric ischemia Cardiac ischemia
Liem et al.121 Rat Mesenteric ischemia Cardiac ischemia
Huda et al.122 Rat Mesenteric ischemia Cardiac ischemiaa central mediator of preconditioning. Although at present 11 iso-
forms of PKC are known, only PKC3 and PKCh have been shown to
undergo translocation in IP. This was ﬁrst demonstrated in rabbits’
hearts by Ping et al. who showed that PKC activation during IP is
isoform selective and may occur without demonstrable changes in
total PKC activity.73 This also resolves the controversy regarding
PKC role in IP, i.e. the PKC blockers used in negative studies may not
have blocked the one or few crucial isoforms responsible for IP. One
target for hypoxia activated PKC3 is the mPTP. It is thought to ﬁrst
interact with mKATP channels, which leads to K
þ inﬂux. This trig-
gers a rise in pH and the subsequent formation of ROS, which
further activates PKC3, inhibiting mPTP. PKC3 also interacts with
subunit 1 V (COIV), increasing the activity of cytochrome C oxidase
(CytCox).74 This presumably increases respiration and energetic
and protects the cell from ROS caused by electron leakage at
complexes 1 and 3.75
PKC3 also interacts with Akt–eNOS. Activation of PKC3 or Akt
(protein kinase B) enhances the eNOS and Akt activities.76 However,
there are reports of Akt inhibition by PKC3 and PKCh.77 Either way,
it appears that there is a direct link between Akt, PKC3 and eNOS.
Another mitochondrial target for PKC3 is Bcl-2 associated death
domain protein (BAD). It plays an anti-apoptotic role under some
conditions by inhibition of BAD.789. Role of protein kinase A
Although the exact role of PKA in IP remains unclear, it has been
shown that cAMP and PKA levels increase after ischemic pre-
conditioning which causes inhibition of calpain. Calpain is a group
of Ca2þ-dependent proteases which are involved in hydrolysis of
structural proteins, namely, Alfa-fodrin during reperfusion. This
reduction in calpain therefore results in a decrease in thestimulus.
Endpoint Proposed mechanism
Reduction in infarct size Humoral, neurogenic
Reduction in infarct size Bradykinin and neuronal pathway
Reduction in infarct size Increased interstitial adenosine levels
Reduction in infarct size Role of iNOS
Reduction in infarct size Myocardial PKC activation through both
humoral and neuronal pathway
Reduction in infarct size Calcitonin gene related peptide
Reduction in infarct size Endogenous opioids
Reduction in infarct size Capsaicin-sensitive sensory nerves
Reduction in infarct size Capsaicin-sensitive sensory nerves and NOS
Reduction in infarct size Mesenteric ischemia adenosine dependent pathway
Reduction in infarct size Inﬂammatory gene suppression
Table 4
Remote ischemic preconditioning studies using renal artery clamping as preconditioning stimulus.
Study Model Site of preconditioning stimulus Site of index ischemia Endpoint Proposed mechanism
Pell et al.123 Rabbit Renal Cardiac ischemia Reduction in infarct size Adenosine receptors and sarcolemmal KATP channels
Takaoka et al.124 Rabbit Renal Cardiac ischemia Reduction in infarct size Adenosine
Singh et al.125 Rat Renal Cardiac ischemia Reduction in infarct size Angiotensin receptors
Lang et al.126 Rat Renal Cardiac ischemia Reduction in infarct size Humoral, neurogenic
U. Sadat / International Journal of Surgery 7 (2009) 490–498494breakdown of membrane protein cytoskeleton and sarcolemmal
fragility, and hence a protection against apoptosis. The protective
effect of PKA is blunted by beta-adrenergic blockade and pharma-
cologically facilitated by beta agonists. However, it remains unclear
whether the beta adrenoreceptor is involved in this response
despite the prominent role of alpha 1 adrenoceptor in PKC-medi-
ated cardioprotection. It is reported in other systems that the
repeated IP might lead to cAMP accumulation and direct PKA
activation independently of the beta adrenoceptor through the
inhibition of phosphodiesterase or direct sensitization of adenylate
cyclase. However, Sanada et al. have attributed the cardioprotective
role of PKA to the activation of p38MAPK and independent of cal-
pain inhibition.79,80 p38MAPK causes phosphorylation of HSP27,
which translocates in the Z bands, thereby increasing the resistance
of the cytoskeleton to conformational changes and fragmentation.
It is thus possible that PKA affords cardioprotection by both calpain
dependent and independent mechanisms. Finally, Manganello et al.
demonstrated that PKA primarily phosphorylates the switch-I
region of G-a13 and inhibits its binding with G-b-g, leading to
inhibition of G-a13 turnover and inactivation of RhoAwhich directly
relaxes vascular smooth muscle and increases regional myocardial
blood ﬂow.43 Rho and Rho kinase inhibition have also been repor-
ted to activate endothelial NO synthase, KATP channels and atten-
uate superoxide production, all of which have been reported to
protect the myocardial against ischemia–reperfusion injury.
10. Role of opioids
Opioid receptors are known to be present in the neuromuscular
regions and cardiomyocytes, especially delta receptors. Delta-
opioid receptors bind to protein kinase C (PKC) and a tyrosine
kinase via interactions with PI3-kinase, oxygen radicals, and
mitochondrial K-ATP channels to afford protection against
ischemia–reperfusion. Opioid release from ischemic tissues does
appear to be involved in the RIPC pathway, just as they play a role in
direct preconditioning. d1-Opioid receptor inhibition abolishes
both direct and remote cardiac preconditioning.81 Patel et al.
demonstrated in a rat model that RIPC before coronary artery
occlusion reduced myocardial infarct size which was abolished byTable 5
Remote ischemic preconditioning studies in humans.
Study Model Site of
preconditioning
stimulus
Protocol Site of i
ischem
Gu¨naydin
et al.108
Human Upper limb Tourniquet inﬂated to 300 mmHg for
3 min and deﬂated for 2 min 2
Myocar
Cheung
et al.129
Human Lower limb Blood pressure cuff inﬂated to
15 mmHg for 5 min and deﬂated 4
Myocar
Hausenloy
et al.130
Human Upper limb Cuff inﬂated to 200 mmHg, 5 min of
inﬂation and 5 min of reperfusion 3
Myocar
Ali et al.131 Human Iliac artery
clamping
Two cycles of 10 min iliac artery
clamping and 10 min declamping
Myocar
and ren
protectnaloxone.82 In contrast, Aitchison et al.83 found not a reduction, but
an increase in infarct size following activation of the k-opioid
receptor in the rat. Coles et al.84 observed a proarrhythmic and not
an antiarrhythmic effect of the k-opioid receptor in pigs. Some
authors stated, however, that the k- and not d-opioid receptors are
involved in the infarct size limiting and arrhythmia suppressant
effect of preconditioning.85,86 It appears that opioids form part of
the humoral pathway that regulates preconditioning. This is sup-
ported by the fact that the protection against ischemia–reperfusion
can be afforded by using efﬂuent containing opioids obtained from
the preconditioned organ.87
Dickson et al.88 could protect virgin acceptor hearts from
infarction by the coronary efﬂuent of previously ischemic pre-
conditioned hearts. This effect could be blocked by the unspeciﬁc
opioid receptor antagonist naloxone. The analysis of the efﬂuent by
radioimmunoassay revealed Met- and Leu-enkephalins. Adminis-
tration of exogenous Met- and Leu-enkephalins to untreated iso-
lated perfused hearts, however, resulted in no protection. Therefore
they concluded that the liberated opioids may not have been
exclusively or directly involved in the mechanism of ‘‘transfused’’
protection.
Miki et al.89 investigated the role of opioids in classical ischemia.
In isolated perfused rabbit hearts they were unable to block the
protection. In in situ hearts naloxone only blocked the protection of
classical preconditioning if preconditioning was performed with
one instead of three ischemia/reperfusion cycles.
In addition to signaling pathways, the potent inhibitory ‘cross-
talk’ that occurs between the opioid d-receptor and b1-adrenergic
receptor signaling pathways may also contribute, at least in part, to
opioid receptor-mediated cardioprotection. It has been shown that
blockade of opioid receptors increases cardiac responsiveness to b-
adrenergic stimulation,90 and conversely, that b-adrenergic
receptor agonists increase opioid receptor number and afﬁnity,91
suggesting a feedback mechanism between these two systems.
11. Role of hypoxia-inducible factor (HIF)
Hypoxia-inducible factor (HIF) is the principal transcription
factor involved in the regulation of transcriptional responses tondex
ia
Endpoint Results Proposed mechanism
dium Cardiac
enzymes
Increase in LDH levels in
preconditioning group
Maintenance of anaerobic
glycolysis in preconditioned
hearts
dium Cardiac
enzymes
(Troponin I)
Increase in Troponin I in
control group
Reduction in myocardial
injury
dium Cardiac
enzymes
(Troponin T)
Increase in Troponin T in
control group
Reduction in myocardial
injury
dium
al
ion
Cardiac
enzymes
(Troponin I)
Less Troponin I area under the
curve in preconditioned group
Reduction in myocardial
injury
U. Sadat / International Journal of Surgery 7 (2009) 490–498 495hypoxia. During hypoxia, HIF-a accumulates and triggers an
increase in expression of genes involved in glycolysis, glucose
metabolism, mitochondrial function, cell survival, apoptosis, and
resistance to oxidative stress.92 Thus it is conceivable that hypoxia
leading to increased reactive oxygen species production leads to
HIF-dependent gene expression,93,94 which results in protection.
Indeed, several HIF-dependent genes have been implicated in the
late phase of preconditioning, including iNOS.95 However, a direct
test of the hypothesis that HIF activation is the common factor
linking the expression of these protective genes has not been
reported.
Given that HIF is a transcription factor and that late pre-
conditioning protection requires gene transcription and translation
of new proteins, one might predict that HIF-mediated protection
would require time between triggering stimulus and the lethal
stress to effect protection. Therefore, it would seem unlikely that
HIF could be involved in the immediate/early phase of IPC.
However, Cai et al. demonstrated the contrary. This response does
not necessarily mean that immediate protection is conferred by the
acute activation of HIF-dependent genes.96 Rather, it is possible that
a decreased constitutive expression of a set of HIF-regulated genes
in the HIF-1aþ/ hearts might have undermined their ability to
activate or transmit the signals necessary for triggering protection
in response to an acute preconditioning stimulus.9212. Species differences
There have been controversies regarding different signaling
pathways involved in IP which usually results from species differ-
ences, e.g. it is generally believed that endogenous adenosine does
not mediate preconditioning in rats, but as pointed out by Head-
rick,97 the relatively high adenosine levels in rat heart during pre-
conditioning require an increase in ant(agonist) receptor
concentration. The readers are referred to the discussion by Przy-
klenk and Kloner on the species (and model) dependency of the
arrhythmia component.98 Przyklenk et al. could not ﬁnd any
translocation of PKC after IP in canines99 and this failure to repro-
duce the original observation in rabbit heart may have been due to
species differences.100 The readers are referred to an excellent
review regarding different aspects of controversies in pre-
conditioning by de Jong et al.10113. Pre-clinical studies
Various important pre-clinical studies have been tabulated in
Tables 1–4.102–126 Details of these tabulated studies can be found in
detailed reviews by Hausenloy and Yellon and Tapuria et al.127,12814. Clinical applications
Despite the diversity of the underlying mechanisms, ischemic
preconditioning continues to emergeas an intriguing technique that
can be effectively used to afford protection against ischemia–
reperfusion. Now we are witnessing the application of this tech-
nique inourclinical practice. Important clinical studies carriedout in
different clinical specialties have been tabulated in Table 5.108,129–131
However, its application in cardiovascular, hepatic and renal surgery
still remains widely unexplored. Future clinical trials may focus on
its utility in patients undergoing coronary revascularization and
renal, hepatic or heart transplants. The next big step should be the
translation of our experience from animal experimentation to clin-
ical practice which may help us explore this intrinsic mechanism of
the body in a new way.Conﬂict of interest
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